improving patient outcomes in urothelial carcinoma with novel antibody–drug conjugates
Published 1 year ago • 152 plays • Length 40:12Download video MP4
Download video MP3
Similar videos
-
2:30
the future of antibody-drug conjugates in urothelial cancer
-
1:58
what’s next for antibody drug conjugates in urothelial carcinoma?
-
31:39
the evolving role of antibody-drug conjugates in the treatment of urothelial carcinoma
-
1:32
antibody-drug conjugates in urothelial carcinoma
-
56:13
advanced/metastatic urothelial carcinoma: understanding novel immunotherapy maintenance strategies
-
55:13
advanced/metastatic urothelial carcinoma: understanding novel immunotherapy maintenance strategies
-
1:21:32
antibody–drug conjugates for solid tumors: progress, possibilities, and implications for care
-
1:02:32
the new immuno-oncology era in early-stage bladder cancer
-
29:06
discovery matters | ep83. antibody drug conjugates
-
27:03
antibody drug conjugates: the end of chemotherapy | 2023 west oncology conference
-
0:38
novel combined adcs in metastatic urothelial carcinoma: insights from esmo 2023
-
0:44
antibody-drug conjugates for advanced bladder cancer
-
1:58
the role of antibody drug conjugates in lung cancer care
-
1:31:33
maximizing the role of adcs in urothelial carcinoma
-
0:46
sequencing adcs and finding novel biomarkers for urothelial carcinoma
-
0:58
adcs in the management of urothelial carcinoma
-
2:07
emerging toxicities associated with adcs
-
35:57
on target: using trop-2-directed therapeutics for urothelial carcinoma
-
1:05:01
tackling the practicalities of antibody–drug conjugate therapy for solid tumors
-
3:06
how effective are adcs in treating metastatic urothelial cancer?
-
1:20
combining adc’s with other novel agents in the frontline treatment of urothelial carcinoma
-
21:33
treatment talk | antibody drug conjugates question & answer